Pfizer’s (PFE) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Pfizer (NYSE:PFE) in a report published on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $45.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on PFE. Argus downgraded shares of Pfizer from a buy rating to a hold rating in a research note on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an outperform rating to a market perform rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Finally, Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a buy rating and a $36.00 price objective on the stock. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of Hold and an average target price of $36.88.

Pfizer Trading Down 1.1 %

Shares of PFE stock opened at $25.41 on Monday. Pfizer has a 12 month low of $25.26 and a 12 month high of $41.33. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $27.19 and its two-hundred day moving average is $28.76. The company has a market cap of $143.86 billion, a PE ratio of 70.57, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.14 earnings per share. Equities analysts predict that Pfizer will post 2.22 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Front Street Capital Management Inc. lifted its holdings in shares of Pfizer by 4.3% during the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares during the period. Castleview Partners LLC lifted its holdings in shares of Pfizer by 2.4% during the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 287 shares during the period. United Bank lifted its holdings in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the period. Compton Capital Management Inc. RI lifted its holdings in shares of Pfizer by 0.5% during the first quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock valued at $3,308,000 after acquiring an additional 300 shares during the period. Finally, GHP Investment Advisors Inc. raised its holdings in shares of Pfizer by 2.4% in the fourth quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock valued at $683,000 after buying an additional 307 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.